What is the most likely consequence of high-dose intravenous epinephrine administration during PALS?

High-dose intravenous epinephrine administration during Pediatric Advanced Life Support (PALS) is primarily associated with the stimulation of beta-adrenergic receptors in the heart, leading to an increase in heart rate. This results in tachycardia, which is a common and expected physiological response when epinephrine is administered in elevated doses. Epinephrine also promotes vasoconstriction through alpha-adrenergic stimulation, enhancing the return of blood to the heart and improving coronary and cerebral perfusion during cardiac arrest scenarios.

In the context of cardiac arrest and resuscitation, the goal of administering high-dose epinephrine is to improve perfusion pressure and consequently increase the chances of successful resuscitation. However, the increase in heart rate is an important consideration, as excessive stimulation of the heart can lead to further complications, including myocardial oxygen demand and potential arrhythmias.

Other potential side effects of epinephrine administration, such as hypotension, bradycardia, or respiratory arrest, are less common or not directly caused by the administration of high-dose epinephrine in this context. Rather, they may arise from differing mechanisms or circumstances unrelated to the immediate effects of epinephrine. Understanding these pharmacological effects is crucial for making informed decisions